EP1904088A4 - Compositions et methodes de traitement du cancer - Google Patents

Compositions et methodes de traitement du cancer

Info

Publication number
EP1904088A4
EP1904088A4 EP06784482A EP06784482A EP1904088A4 EP 1904088 A4 EP1904088 A4 EP 1904088A4 EP 06784482 A EP06784482 A EP 06784482A EP 06784482 A EP06784482 A EP 06784482A EP 1904088 A4 EP1904088 A4 EP 1904088A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
treating cancer
cancer
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06784482A
Other languages
German (de)
English (en)
Other versions
EP1904088A2 (fr
Inventor
Andrea Alan D D
Toshiyasu Taniguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of EP1904088A2 publication Critical patent/EP1904088A2/fr
Publication of EP1904088A4 publication Critical patent/EP1904088A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP06784482A 2005-05-24 2006-05-24 Compositions et methodes de traitement du cancer Withdrawn EP1904088A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68413605P 2005-05-24 2005-05-24
PCT/US2006/020390 WO2006127978A2 (fr) 2005-05-24 2006-05-24 Compositions et methodes de traitement du cancer

Publications (2)

Publication Number Publication Date
EP1904088A2 EP1904088A2 (fr) 2008-04-02
EP1904088A4 true EP1904088A4 (fr) 2010-03-31

Family

ID=37452873

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06784482A Withdrawn EP1904088A4 (fr) 2005-05-24 2006-05-24 Compositions et methodes de traitement du cancer

Country Status (5)

Country Link
EP (1) EP1904088A4 (fr)
JP (1) JP2008545965A (fr)
AU (1) AU2006249807A1 (fr)
CA (1) CA2609751A1 (fr)
WO (1) WO2006127978A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007325900A1 (en) * 2006-10-20 2008-06-05 Dnar, Inc. DNA damage repair inhibitors and methods for treating cancer
EP2134855A4 (fr) * 2007-03-12 2011-01-05 Dana Farber Cancer Inst Inc Pronostic, diagnostic et utilisations dans le traitement du cancer de fanci et des agents de modulation de fanci
WO2012009475A1 (fr) * 2010-07-14 2012-01-19 Oregon Health & Science University Méthodes de traitement du cancer par inhibition de la déméthylase 1 spécifique de la lysine
EP3073825A4 (fr) * 2013-11-25 2017-06-21 The University of Toledo Inhibiteurs de ercc1-xpf et leurs méthodes d'utilisation
CN116602954A (zh) * 2015-04-22 2023-08-18 新纳特产品公司 共晶组合物及其药物用途
BR112018076306A2 (pt) 2016-06-17 2019-03-26 Magenta Therapeutics, Inc. composições e métodos para a supressão de células cd117+

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005081783A2 (fr) * 2004-01-30 2005-09-09 Dana Farber Cancer Institute Procedes pour determiner et quantifier l'exposition a des rayonnements ou a des genotoxines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002218006A1 (en) * 2000-11-03 2002-05-15 Dana Farber Cancer Institute Compositions and methods for the diagnosis of cancer
US20030188326A1 (en) * 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005081783A2 (fr) * 2004-01-30 2005-09-09 Dana Farber Cancer Institute Procedes pour determiner et quantifier l'exposition a des rayonnements ou a des genotoxines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAGBY GROVER C ET AL: "Cisplatin and the sensitive cell.", NATURE MEDICINE MAY 2003, vol. 9, no. 5, May 2003 (2003-05-01), pages 513 - 514, XP002550337, ISSN: 1078-8956 *
CHIRNOMAS DEBORAH ET AL: "Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway", MOLECULAR CANCER THERAPEUTICS, vol. 5, no. 4, April 2006 (2006-04-01), pages 952 - 961, XP002550338, ISSN: 1535-7163 *

Also Published As

Publication number Publication date
JP2008545965A (ja) 2008-12-18
WO2006127978A2 (fr) 2006-11-30
AU2006249807A1 (en) 2006-11-30
WO2006127978A3 (fr) 2009-04-30
EP1904088A2 (fr) 2008-04-02
CA2609751A1 (fr) 2006-11-30

Similar Documents

Publication Publication Date Title
EP1663259A4 (fr) Compositions et methodes de traitement du cancer
NO20200775A1 (no) Fremgangsmåter og sammensetninger for behandling av kreft
EP1755391A4 (fr) Methodes et compositions de traitement de neuropathies
CR10667A (es) Compositions and methods for diagnosing and treating cancer
EP1907858A4 (fr) Compositions et procedes de traitement et de diagnostic du cancer
EP1667680A4 (fr) Methodes combinees de traitement du cancer
EP1796666A4 (fr) Methodes et compositions de traitement de l'hyperlipidemie
EP1961065A4 (fr) Compositions et procedes pour diagnostiquer et traiter un cancer
EP2207424A4 (fr) Compositions et procédés de traitement du purpura
EP1858542A4 (fr) Compositions et methodes permettant de traiter la permeabilite vasculaire
EP1639090A4 (fr) Compositions et methodes de traitement et de diagnostic du cancer
EP2032166A4 (fr) Compositions et procedes de diagnostic et de traitement du cancer
EP1987141A4 (fr) Compositions et procédés de traitement des maladies médiées par le collagène
EP1816953A4 (fr) Instrument de detection et de traitement du cancer
DE602005015234D1 (de) Zusammensetzungen zur wäschebehandlung
DE602005014252D1 (de) Zusammensetzungen zur wäschebehandlung
EP2176283A4 (fr) Methodes et compositions de traitement des maladies cerebrales
EP2187880A4 (fr) Compositions et procédés de traitement de la dégénérescence maculaire
EP1868628A4 (fr) Composes, compositions et methodes de traitement des infections a poxvirus
PL2529626T3 (pl) Kompozycje i sposoby leczenia lub zapobiegania nowotworowi okrężnicy
EP2037743A4 (fr) Compositions de pâte et procédés associés
EP2068865A4 (fr) Procédés et compositions pour traitement thérapeutique
EP2340027A4 (fr) Procédés et compositions destinés au traitement du cancer
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
EP1626711A4 (fr) Compositions et methodes de traitement anticancereux

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071221

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

DAX Request for extension of the european patent (deleted)
R17D Deferred search report published (corrected)

Effective date: 20090430

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DANA FARBER CANCER INSTITUTE, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/00 20060101ALI20090504BHEP

Ipc: A61K 38/00 20060101ALI20090504BHEP

Ipc: G01N 33/53 20060101AFI20090504BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100301

17Q First examination report despatched

Effective date: 20100616

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DANA-FARBER CANCER INSTITUTE, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121201